Breakfast Brief with Univ.-Prof. Dr. Shahrokh F. Shariat
Univ.-Prof. Dr. Shahrokh F. Shariat, Chairman at the Department of Urology, Medical University Vienna, presents the most relevant urothelial carcinoma studies of ASCO Congress 2018.
The following abstracts are discussed:
Source: ASCO Annual Meeting 2018
- Abstract 4535:
Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.
- Abstract 4506:
A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
- Abstract 4507
Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase 2 PURE-01 study.
- Abstract LBA 1509:
Pan-cancer microsatellite instability to predict for presence of Lynch syndrome.
- Abstract 4503:
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).
- Abstract 4513:
Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.
- Abstract 4505:
Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).
- Abstract 4504:
Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).
- Abstract 4506: